Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

ABERDEEN, Scotland, Jan. 25, 2021 /PRNewswire/ -- Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMER™ biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of...

from PR Newswire: https://ift.tt/3sSeggO